Meeting
2017 ASCO Annual Meeting
High-fidelity genome editing using NextGEN CRISPR (Clo51-dCas9) system for the production of allogeneic CAR-T cells.
Authors
Xinxin Wang
Poseida Therapeutics, Inc., San Diego, CA
Xinxin Wang , Xianghong Li , Burton Barnett , Christopher Martin , David Hermanson , Jenessa Smith , Srinivas Rengarajan , Yening Tan , Min Tong , Rebecca Codde , Eric M. Ostertag , Devon J. Shedlock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research,Immunotherapy
Sub Track
Cellular Immunotherapy
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3048)
DOI
10.1200/JCO.2017.35.15_suppl.3048
Abstract #
3048
Poster Bd #
143
Abstract Disclosures
Similar Posters
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Combinatorial IL13Rα2 chimeric antigen receptor-T cells plus checkpoint blockade to treat solid tumors in murine and canine models.
First Author: Yibo Yin
Poster
2021 ASCO Annual Meeting
Nivolumab/ipilimumab primed immunotransplant in post-CAR-T and post-ASCT DLBCL.
First Author: Bailey Gleason Fitzgerald
Poster
2017 ASCO Annual Meeting
Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).
First Author: Jerome Galon
Poster
2024 ASCO Annual Meeting
Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors.
First Author: Jacob Stephen Thomas